S. 2516 (112th): Food and Drug Administration Safety and Innovation Act
May 7, 2012
112th Congress, 2011–2013
Died in a previous Congress
This bill was introduced on May 7, 2012, in a previous session of Congress, but was not enacted.
Thomas “Tom” Harkin
Senator from Iowa
Read Text »
Last Updated: May 7, 2012
Length: 314 pages
- See Instead:
S. 3187 (same title)
Enacted — Signed by the President — Jul 9, 2012
About the bill
- Full Title
An original bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes.
Legislative action may be ocurring on one of these bills in lieu of or in parallel to action on this bill.
Enacted — Signed by the President
Jul 9, 2012
Last Action: May 30, 2012
- What is a bill?
The “S.” in “S. 2516” means this is a Senate bill in the United States Congress. A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
The bill’s title was written by its sponsor.
- Committee Assignments
The committee chair determines whether a bill will move past the committee stage.
There have been no votes related to this bill.
- Subject Areas
- Find Similar Bills
Search for similar bills.
Links & tools
Click a format for a citation suggestion:
Civic Impulse. (2015). S. 2516 — 112th Congress: Food and Drug Administration Safety and Innovation Act. Retrieved from https://www.govtrack.us/congress/bills/112/s2516
“S. 2516 — 112th Congress: Food and Drug Administration Safety and Innovation Act.” www.GovTrack.us. 2012. April 1, 2015 <https://www.govtrack.us/congress/bills/112/s2516>
|title=S. 2516 (112th)
|accessdate=April 1, 2015
|author=112th Congress (2012)
|date=May 7, 2012
|quote=Food and Drug Administration Safety and Innovation Act